Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Breckenridge Pharmaceutical, a marketer of a range of generic prescription products in many therapeutic categories, has rolled out Letrozole 2.5mg Tablets.
Subscribe to our email newsletter
The launch follows the approval from the US Food and Drug Administration for Letrozole 2.5mg Tablets’ abbreviated new drug application (ANDA).
Letrozole tablets are bioequivalent to Novartis’ Femara, which contains 2.5mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis).
Femara tablets are approved for the adjuvant treatment of postmenopausal women with hormone receptor-positive early stage breast cancer.